Biomarker Associations in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955921

Authors

Dora Spantler

Tihamer Molnar

Diana Simon

Timea Berki

Andras Buki

Attila Schwarcz

Peter Csecsei

Affiliations

Soon will be listed here.

Abstract

The prognosis for patients with aneurysmal subarachnoid hemorrhage (aSAH) is heavily influenced by the development of delayed cerebral ischemia (DCI), but the adequate and effective therapy of DCI to this day has not been resolved. Multiplex serum biomarker studies may help to understand the pathophysiological processes underlying DCI. Samples were collected from patients with aSAH at two time points: (1) 24 h (Day 1) and (2) 5−7 days after ictus. Serum concentrations of eotaxin, FGF-2, FLT-3L, CX3CL1, Il-1b, IL-4, IP-10, MCP3, and MIP-1b were determined using a customized MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A multiplex assay. The functional outcome was defined by the modified Rankin scale (favorable: 0−2, unfavorable: 3−6) measured on the 30th day after aSAH. One-hundred and twelve patients with aSAH were included in this study. The median level of CX3CL1 and MCP-3 measured on Days 5−7 were significantly higher in patients with DCI compared with those without DCI (CX3CL1: with DCI: 110.5 pg/mL, IQR: 82−201 vs. without DCI: 82.6, 58−119, p = 0.036; and MCP-3: with DCI: 22 pg/mL (0−32) vs. without DCI: 0 (0−11), p < 0.001). IP-10, MCP-3, and MIP-1b also showed significant associations with the functional outcome after aSAH. MCP-3 and CX3CL1 may play a role in the pathophysiology of DCI.

Citing Articles

Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage.

Ding R, Wu L, Wei S, Lu H, Qin X, Liu X Proteome Sci. 2024; 22(1):11.

PMID: 39604965 PMC: 11600900. DOI: 10.1186/s12953-024-00236-x.

Circulating inflammatory biomarkers and risk of intracranial aneurysm: a Mendelian randomization study.

Fang J, Cao Y, Ni J Eur J Med Res. 2024; 29(1):17.

PMID: 38173028 PMC: 10763118. DOI: 10.1186/s40001-023-01609-2.

Potential application of peripheral blood biomarkers in intracranial aneurysms.

Wu Y, Zhao Z, Kang S, Zhang L, Lv F Front Neurol. 2023; 14:1273341.

PMID: 37928138 PMC: 10620808. DOI: 10.3389/fneur.2023.1273341.

Pre-operative prognostic nutrition index and post-operative pneumonia in aneurysmal subarachnoid hemorrhage patients.

Xu M, Zhang L, Wang J, Cheng L, Chen C, Li S Front Neurol. 2023; 14:1045929.

PMID: 37188306 PMC: 10177408. DOI: 10.3389/fneur.2023.1045929.

References

Grosset D, Straiton J, Du Trevou M, Bullock R . Prediction of symptomatic vasospasm after subarachnoid hemorrhage by rapidly increasing transcranial Doppler velocity and cerebral blood flow changes. Stroke. 1992; 23(5):674-9. DOI: 10.1161/01.str.23.5.674. View

Lauro C, Catalano M, Trettel F, Limatola C . Fractalkine in the nervous system: neuroprotective or neurotoxic molecule?. Ann N Y Acad Sci. 2015; 1351:141-8. DOI: 10.1111/nyas.12805. View

Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E . CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci. 2011; 31(45):16327-35. PMC: 6633249. DOI: 10.1523/JNEUROSCI.3611-11.2011. View

Koenig H, Chen J, Sieg E . Delayed Cerebral Ischemia: Is Prevention Better Than Treatment?. J Neurosurg Anesthesiol. 2021; 33(3):191-192. PMC: 8195732. DOI: 10.1097/ANA.0000000000000773. View

Kim G, Kellner C, Hahn D, Desantis B, Musabbir M, Starke R . Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008; 109(1):38-43. DOI: 10.3171/JNS/2008/109/7/0038. View

Chang J, Triano M, Corbin M, Desale S, Liu A, Felbaum D . Transcranial Doppler velocity and associations with delayed cerebral ischemia in aneurysmal subarachnoid Hemorrhage. J Neurol Sci. 2020; 415:116934. DOI: 10.1016/j.jns.2020.116934. View

Akhter R, Shao Y, Formica S, Khrestian M, Bekris L . TREM2 alters the phagocytic, apoptotic and inflammatory response to Aβ in HMC3 cells. Mol Immunol. 2021; 131:171-179. PMC: 8147571. DOI: 10.1016/j.molimm.2020.12.035. View

Righy C, Turon R, Freitas G, Japiassu A, de Castro Faria Neto H, Bozza M . Hemoglobin metabolism by-products are associated with an inflammatory response in patients with hemorrhagic stroke. Rev Bras Ter Intensiva. 2018; 30(1):21-27. PMC: 5885227. DOI: 10.5935/0103-507x.20180003. View

Dahinden C, Geiser T, Brunner T, Von Tscharner V, Caput D, Ferrara P . Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med. 1994; 179(2):751-6. PMC: 2191381. DOI: 10.1084/jem.179.2.751. View

10.

Wang B, Li X, Dong T, Gao F, Li Z, Ma Z . Expression of interferon regulatory factor 4 and inflammation in secondary injury of intracerebral haemorrhage. Folia Neuropathol. 2021; 59(3):291-297. DOI: 10.5114/fn.2021.109200. View

11.

Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M . Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci. 2002; 15(10):1663-8. DOI: 10.1046/j.1460-9568.2002.02007.x. View

12.

Velat G, Kimball M, Mocco J, Hoh B . Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg. 2011; 76(5):446-54. DOI: 10.1016/j.wneu.2011.02.030. View

13.

Vergouwen M, Vermeulen M, van Gijn J, Rinkel G, Wijdicks E, Muizelaar J . Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010; 41(10):2391-5. DOI: 10.1161/STROKEAHA.110.589275. View

14.

Papaioannou V, Budohoski K, Placek M, Czosnyka Z, Smielewski P, Czosnyka M . Association of transcranial Doppler blood flow velocity slow waves with delayed cerebral ischemia in patients suffering from subarachnoid hemorrhage: a retrospective study. Intensive Care Med Exp. 2021; 9(1):11. PMC: 7994457. DOI: 10.1186/s40635-021-00378-8. View

15.

Lu H, Shi J, Chen H, Hang C, Wang H, Yin H . Expression of monocyte chemoattractant protein-1 in the cerebral artery after experimental subarachnoid hemorrhage. Brain Res. 2009; 1262:73-80. DOI: 10.1016/j.brainres.2009.01.017. View

16.

Alaraj A, Charbel F, Amin-Hanjani S . Peri-operative measures for treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage. Neurol Res. 2009; 31(6):651-9. DOI: 10.1179/174313209X382395. View

17.

Loch Macdonald R . Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2013; 10(1):44-58. DOI: 10.1038/nrneurol.2013.246. View

18.

de Rooij N, Linn F, van der Plas J, Algra A, Rinkel G . Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007; 78(12):1365-72. PMC: 2095631. DOI: 10.1136/jnnp.2007.117655. View

19.

Lahrtz F, Piali L, Nadal D, Pfister H, Spanaus K, Baggiolini M . Chemotactic activity on mononuclear cells in the cerebrospinal fluid of patients with viral meningitis is mediated by interferon-gamma inducible protein-10 and monocyte chemotactic protein-1. Eur J Immunol. 1997; 27(10):2484-9. DOI: 10.1002/eji.1830271004. View

20.

Sehba F, Pluta R, Zhang J . Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol. 2010; 43(1):27-40. PMC: 3023855. DOI: 10.1007/s12035-010-8155-z. View